The use of lupinol and stigmasterol in CCA can disrupt tumor angiogenesis, reduce the growth of xenografts of CCA tumors, and lower the CD31-positive blood vessel content and macrophage recruitment after treatment. Here, PECAM1 is linked to cholangiocarcinoma.